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Cysteine-Rich Antifungal Proteins from Filamentous Fungi
are Promising Bioactive Natural Compounds in
Anti-Candida Therapy
La´szlo´ Galgo´czy,*[a, b] Annie Yap,[c] and Florentine Marx*[c]
Abstract: The emerging number of life-threatening invasive
fungal infections caused by drug-resistant Candida strains
urges the need for the development and application of
fundamentally new and safe antifungal strategies in the
clinical treatment. Recent studies demonstrated that the
extracellular cysteine-rich and cationic antifungal proteins
(crAFPs) originating from filamentous fungi, and de novo
designed synthetic peptide derivatives of these crAFPs
provide a feasible basis for this approach. This mini-review
focuses on the global challenges of the anti-Canidia therapy
and on the crAFPs as potential drug candidates to overcome
existing problems. The advantages and limitations in the use
of crAFPs and peptide derivatives compared to those of
conventional antifungal drugs will also be critically dis-
cussed.
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1. Introduction
Nowadays, the successful treatment of life-threatening human
fungal infections caused by Candida species has become more
challenging as a consequence of (i) the current epidemiolog-
ical changes in the genus, (ii) the limited number of effective
antifungal drugs in the clinical therapy, and (iii) the emerging
number of drug-resistant isolates. These three factors indicate
that recent therapies based on licensed antifungal agents have
several limitations for a successful treatment of Candida
infections and to overcome antifungal drug-resistance of
Candida species. Therefore, there is an urgent need for the
development of new, alternative therapeutics and strategies in
anti-Candida therapy. Natural compounds such as antifungal
peptides and proteins with potent anti-yeast activity provide
promising alternatives to the conventionally applied licensed
antifungal drugs. In this review, we address the current global
challenges in the treatment of Candida infections, and discuss
the potential of secreted cationic, cysteine (Cys)-rich anti-
fungal proteins (crAFPs) originating from filamentous asco-
mycetes and the peptide derivatives thereof as promising
candidates for future antifungal drug development.
2. Global Challenges in Treatment of Candida
Infections
2.1 Epidemiological Changes
The genus Candida is represented by ~150 yeast species, but
only 15 of them have been described from human infections
(candidiasis);[1] and five species in particular (Candida
albicans, Candida glabrata, Candida parapsilosis, Candida
tropicalis or Candida krusei) have been identified from 95 %
of all documented cases.[1,2] Candida species belong to the
normal human microbiota. In healthy individuals they colonize
mainly the skin, mucosal surfaces of the oral cavity, gastro-
intestinal and urogenital tracts without causing any symp-
toms.[3] Stress factors that weaken the immune system of the
host may disturb this ecosystem and result in Candida
overgrowth, causing non-fatal, but disagreeable and very often
recurrent superficial infections. Risk factors are for example
surgical interventions, nosocomial bacterial infections, medi-
cations (antibiotics, hormone and chemotherapies), parenteral
nutrition, mechanical ventilation as well as diseases that
compromise the host‘s immune status (HIV infection, diabetes,
hemato-oncological malignancies).[4–7] Moreover, Candida
pathogenicity is closely linked to the ability of the fungus to
attach not only to the patient‘s tissues but also to synthetic
[a] L. Galgóczy
Institute of Plant Biology, Biological Research Centre, Hungarian
Academy of Sciences, Temesvári krt. 62, H-6726 Szeged (Hungary)
[b] L. Galgóczy
Department of Microbiology, Faculty of Science and Informatics,
University of Szeged, Közép fasor 52, H-6726 Szeged (Hungary)
E-mail: galgoczi.laszlo@brc.mta.hu
[c] A. Yap, F. Marx
Division of Molecular Biology, Biocenter, Medical University of
Innsbruck, Innrain 80–82, A-6020 Innsbruck (Austria)
E-mail: florentine.marx@i-med.ac.at
© 2019 The Authors. Published by Wiley-VCH Verlag GmbH &
Co. KGaA. This is an open access article under the terms of the
Creative Commons Attribution License, which permits use, dis-
tribution and reproduction in any medium, provided the original
work is properly cited.
Isr. J. Chem. 2019, 59, 360–370 © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 360
Review
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
medical devices (dentures, central venous catheters, shunts,
etc.) where biofilm formation hampers therapeutic treatment
efficacy.[5] Depending on the overall health status of the
patient, Candida cells may invade deeper into tissues and
disseminate through the human body causing life-threatening
blood-stream infections. Candida species are responsible for
the most cases of invasive fungal infections with high mortal-
ity rates in immunocompromised patients all over the world.[8]
C. albicans is still the most frequently isolated Candida from
human infections; however, the rapidly increasing number of
non-albicans Candida species (NAC) has been reported in the
last years.[9] NAC species show different distributions in
diverse age groups and geographical locations. While C.
albicans is the most prevalent pathogenic Candida species in
patients aged up to 18 years, C. parapsilosis and C. glabrata is
mostly isolated from neonates and elders, respectively. C.
glabrata is the most common NAC species in North America
and northern part of Europe, while C. parapsilosis in Southern
Europe, Africa, India, and Latin America.[10,11] In addition,
Candida auris as an emerging human pathogenic yeast
represents a serious global health threat nowadays.[12] These
recent epidemiological changes have an important clinical
impact as the NAC species show diminished susceptibility to
the first-line therapeutically applied antifungal agents, which
are generally effective against C. albicans.[13]
2.2 Limitations in Clinical Therapy
Today, only three groups of licensed antifungal drugs are
applied for treatment of life-threatening blood-stream Candida
infections (candidemia) and invasive candidiasis when the
infection affects more than one organ of the patient. These are
the triazoles (fluconazole, voriconazole, posaconazole), the
echinocandins (caspofungin, micafungin, anidulafungin), and
polyenes (different formulations of amphotericin B).[14] Echi-
nocandins and triazoles are better tolerated by the patients
than amphotericin B. Due to the risk of high toxicity
(nephrotoxicity), amphotericin B is no more considered as an
option in the treatment. Lipid formulations of amphotericin B
diminish the nephrotoxic effect, but are significantly more
expensive than the well-tolerated fluconazole and more toxic
than echinocandins, hence its application is considered only in
specific situations.[15] As fluconazole is inexpensive and read-
ily available worldwide, it is the most frequently prescribed
triazole to treat Candida infections.[16] However, voriconazole
is more efficient than fluconazole, but considering the high
therapeutic cost it is prescribed only when the infective
Candida strain is fluconazole-resistant.[17] Posaconazole is
approved for use as a prophylactic agent,[18] but its therapeutic
application is considered against fluconazole-, voriconazole-
and cross-resistant Candida isolates.[19] Recently, echinocan-
dins are considered as the most effective antifungals and are
used extensively to treat candidemia and invasive candidiasis
due to the broad-spectrum against Candida species and
generally mild adverse effects, but their application is limited
by the high costs of echinocandin therapy.[20] Despite the
successful introduction and application of the above men-
tioned three antifungal drug groups in the clinical therapy,
Candida infections with fatal outcome are becoming more
frequent as a consequence of emerging resistance mecha-
nisms.[21]
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2.3 Emergence of Antifungal Drug-Resistance
All developed resistance mechanisms directly or indirectly
have an impact on the antifungal drug target. Amphotericin B
binds to ergosterol, the main sterol in the fungal cell
membrane, and forms membrane-spanning pores resulting in
the lysis of the fungal cell. Alteration of the cytoplasmic
membrane lipid composition reduces the affinity of amphoter-
icin B for the cell membrane and renders the fungus less
susceptible or even resistant against this antifungal agent.[22]
Azoles inhibit the biosynthesis of ergosterol, causing the
intracellular accumulation of toxic sterol intermediates and
inducing cell membrane stress. Overexpression of different
efflux pumps and enzymes playing a role in ergosterol
biosynthesis or their mutations in the drug-binding domain
contribute to the resistance mechanism.[22] Echinocandins are
noncompetitive inhibitors of 1,3-b-D-glucan synthase, an
integral component of the fungal cell wall biosynthesis, and its
dysfunction leads to loss of cell wall integrity. The mutation in
the catalytic domain of the (1,3)-b-D-glucan synthase is the
most common resistance mechanism against this drug class.[22]
As fluconazole and echinocandins are the first- or second-line
applied antifungals, several Candida species show resistance
to these medications. Global surveillance programs demon-
strated that the increasing incidence of fluconazole resistance
is a particular problem with Candida infections, especially
with C. glabrata and C. krusei. However, the resistance
against echinocandins was detected only within two years after
their clinical launch and almost 3% of C. glabrata isolates
have already developed resistance mechanisms.[21,23,24] Multi-
drug resistance to azoles, echinocandins, and polyenes is still
uncommon within the genus, but its emergence in several
Candida species has been reported and points towards an
increasing trend among C. glabrata and C. auris isolates.[25]
3. Anti-Candida Proteins from Filamentous
Ascomycetes
3.1 Origin and Phylogeny
Filamentous ascomycetes, especially the members of the class
Eurotiomycetes are a rich source for extracellular crAFPs.[26]
They share common features such as a low molecular mass,
the presence of six to eight Cys residues that form three to
four intramolecular disulfide bonds which provide a high
stability against protease degradation, extreme temperatures
and within a broad pH range. Another common feature is their
cationic character based on a high amount of arginine (Arg),
lysine (Lys) and histidine (His) residues in the primary
structure. The secreted crAFPs differ in their amino acid
sequences, but conserved homologous parts in the primary
structure can be identified at the flanking regions of Cys.[27] A
recently published phylogenetic analysis demonstrated that
crAFPs can be divided into four different groups based on
these conserved regions: proteins with characteristic amino
acid motifs to (1) Aspergillus giganteus antifungal protein
(AFP-clade), (2) Penicillium chrysogenum antifungal protein
(PAF-clade), (3) Penicillium brevicompactum ‘bubble protein’
(BP-clade), and (4) Neosartorya (Aspergillus) fischeri anti-
fungal protein 2 (NFAP2-clade).[26] It has to be noted that one
species could produce more than one AFP belonging to the
same clade, e.g. PAF and PAFB (PAF-clade proteins) from P.
chrysogenum;[28] or to different clades e.g. NFAP (PAF-clade
protein) and NFAP2 (NFAP2-clade protein) from N. fi-
scheri.[29] The crAFPs are mainly effective against filamentous
fungi, but potent anti-yeast activity has been reported recently
only for some representatives belonging to the PAF- (AnAFP,
FPAP, PAF, PAFB), BP-(BP), and NFAP2-clade (NFAP2),
respectively.[26,28–32] These proteins, their origin and physico-
chemical properties are summarized in Table 1.
3.2 Protein Structure
The crAFPs are expressed as prepro proteins and the pre- and
pro-sequence are cleaved off from the N-terminus during the
maturation process and secretion (Figure 1).[27] The proper
maturation of crAFPs is crucial for the full antifungal
activity.[44] The primary structure of crAFPs belonging to
distinct clades show low homology, but it contains six or eight
Cys residues. Three intramolecular disulfide bridges adopting
a common abcabc pattern are formed in the members of the
PAF- (AnAFP, PAF, PAFB, FPAP) and NFAP2-clades
(NFAP2); or four disulfide bonds are formed connecting the
loop region to sheet 1, and the sheet 1 to the base of sheet 2,
as it is found in the members of the BP-clade (BP) (Fig-
ure 1).[26,45] The correct disulfide bridge pattern is essential for
the structural stability and the function.[44]
Electronic circular dichroism spectroscopy of PAF, PAFB,
NFAP2 and structural prediction of AnAFP and FPAP (in this
review) revealed that these crAFPs have a common b-pleated
conformation due to the presence of numerous b-strands in
their secondary structure (Figure 2).[28,29,46]
Based on nuclear magnetic resonance (NMR) spectro-
scopy,[28,47] X-ray crystallography,[45] and in silico homology
modeling prediction experiments (in this review) the members
of PAF- and BP-clade anti-yeast proteins share a very similar
overall tertiary structure; a b-barrel topology, in which five
antiparallel b-strands connected by loops create two orthogo-
nally packed b-sheets. The loops are solvent exposed and
flexible suggesting a role in the binding to the fungal target
cell.[47,48] The above discussed structural features have been
confirmed experimentally for PAF,[47,49] PAFB,[28] and BP,[45]
and predicted for AnAFP, and FPAP (the last two in this
review, Supporting Information) (Figure 3). NMR investiga-
tions of NFAP2 are in progress.[50] These proteins have an
amphipathic surface with alternating positively- and nega-
tively-charged patches (Figure 3). It is assumed that apart
from the correct disulfide bonding between the Cys residues, a
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hidden central hydrophobic core coordinates the proper
folding and the formation of a stable protein structure.[44,47]
3.3 Recombinant Production
From economic view, one of the limiting factors for future
application of crAFPs as anti-Candida compounds is the low-
yield production by the native producers.[27] To meet this
requirement, a P. chrysogenum-based expression system was
developed for the optimal bulk production of PAF,[46] PAFB,[28]
and NFAP2.[50] This system is reliable considering the correct
protein processing, folding, and disulfide bond formation.[46,50]
Applying P. chrysogenum as expression host, crAFPs do not
undergo any posttranslational modifications, except for the
required cleavage of the prepro-sequence (Figure 1) and
folding. This recently reported system represents the perfect
tool for cost-effective generation of crAFPs in high yields.[46,50]
Notably, P. chrysogenum is fermentable and generally recog-
nized as safe (GRAS) organism by the US Food and Drug
Administration.[51]
3.4 Chemical Synthesis
In comparison with time-intensive protein production by
fermentation, chemical synthesis of full-length crAFPs is fast,
but still not cost-effective considering the final protein yield.
Different de novo designed crAFP variants were chemically
synthesized in low amounts for preliminary structural inves-
tigations and antifungal activity testing before the more time-
intensive generation of the respective genetically engineered
fungal strains was started to produce these antifungal proteins
in high amounts (unpublished). Studies regarding the synthetic
production of PAF and NFAP2 proved that the method of
native chemical ligation of peptide fragments using solid-
phase fluorenylmethyloxycarbonyl (Fmoc) chemistry com-
bined with an additional oxidation step represents a fast and
reliable method to synthesize functionally active crAFPs.[50,52]
Moreover, the specific protection of Cys sulfhydryl groups
within oxidative conditions allows the formation of the correct
disulfide bridge pattern or their variation to investigate the
structure-function relation in crAFPs.[50,52] The current limi-
tation of this method is the risk for disulfide bond formation
deviating from the correct pattern, and for bond disruption in
the presence of reducing agents during the synthesis process;
however several solutions are available to overcome these
methodological problems.[52,53] Furthermore, this method is
valuable to modify the amino acid sequence to discriminate
Table 1. Amino acid sequence and in silico predicted physicochemical properties of crAFPs with anti-yeast activity.
Protein Origin (isolate) UniProtKB
ID[33]
Number of
amino
acids
Molecular
weight
(kDa)[34]
Number
of
Cys
Number of
Lys/Arg/
His
Theoretical
isoelectric
point[34]
Estimated
charge
at pH 7[35]
GRAVY[34]
PAF-clade
LSKYGGECSLEHNTCTYRKDGKNHVVSCPSAANLRCKTDRHHCEYDDHHKTVDCQTPV
AnAFP Aspergillus niger
KCTC 2025
A0A117E0B2 58 6.6 6 5/3/6 7.14 +1.2 1.076
LEYWGKCTKAENRCKYKNDKGKDVLQNCPKFDNKKCTKDGNSCKWDSASKALTCY
FPAP Fusarium polyphialidi-
cum
SZMC 11042
E1UGX4 55 6.4 6 12/1/0 9.10 +5.7 1.291
AKYTGKCTKSKNECKYKNDAGKDTFIKCPKFDNKKCTKDNNKCTVDTYNNAVDCD
PAF Penicillium chrysoge-
num
Q176
Q01701 55 6.3 6 13/0/0 8.93 +4.7 1.375
LSKFGGECSLKHNTCTYLKGGKNHVVNCGSAANKKCKSDRHHCEYDEHHKRVDCQTPV
PAFB Penicillium chrysoge-
num
Q176
A0A167QQK7 58 6.5 6 8/2/6 8.83 +5.2 1.031
BP-clade
DTCGSGYNVDQRRTNSGCKAGNGDRHFCGCDRTGVVECKGGKWTEVQDCGSSSCKGTSNGGATC
BP Penicillium
brevicompactum
Dierckx
G5DC88 64 6.6 8 4/4/1 7.70 +0.9 0.867
NFAP2-clade
IATSPYYACNCPNNCKHKKGSGCKYHSGPSDKSKVISGKCEWQGGQLNCIAT
NFAP2 Neosartorya fischeri
NRRL181
A0A1D0CRT2 52 5.6 6 7/0/2 9.02 +5.2 0.731
GRAVY: grand average of hydropathy value. Bold and underlined letters indicate the g-core motif(s).
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essential from non-essential structural elements determining
crAFPs function. Considering the fact that Fmoc solid-phase
peptide synthesis is becoming more economic nowadays,[54]
this chemical method could provide an alternative for the
industrial-scale production of ultrapure crAFPs in the future.
4. Anti-Candida Activity of crAFPs
4.1 In Vitro Anti-Candida Activity
The in vitro susceptibility of different clinically relevant
Candida species to crAFPs is summarized in Table 2.
However, it has to be noted that the detected minimal
inhibitory concentrations (MICs) strongly depend on the
applied test medium. It was demonstrated that the MIC of
NFAP2 is higher in a standard high cationic clinical
susceptibility (HCCS) test medium mimicking the composi-
tion of human extracellular environment than in a low ionic
Figure 1. Primary structure of anti-yeast crAFPs isolated from Eurotiomycetes. ClustalW multiple alignment of the prepro-sequences and the
sequences of mature proteins were generated with the BioEdit program[36] and visualized with Jalview version 2.10.3b1.[37] The cleavage site of
the predicted signal sequence (pre-sequence indicated by grey line) was predicted by SignalP1 4.1 server.[38] Connective orange lines between
Cys residues (C in black frame) indicate disulfide bridge formations. The ClustalX default color scheme was applied in the alignment (http://
www.jalview.org/help/html/colourSchemes/clustal.html) to show similarity.[37] Brackets in the sequence of PAFB indicate that this protein is
expressed in 58 amino acid full-length form into the supernatant, however the leucine (L) and the serine (S) are cleaved from the N-terminus
with time, generating the 56 amino acid sfPAF form which served for the tertiary structure determination.[28]
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Figure 2. Secondary structure and relative solvent accessibility (RSA) of anti-yeast crAFPs isolated from Eurotiomycetes. Linear representation
of secondary structures and RSA were generated from the respective annotated (PAFB, PAF, BP) or predicted (AnAFP and FPAP) .pdb file of
tertiary structure (Protein Data Bank IDs: PAFB-2nc2, PAF-2mhv, BP-1uoy) with POLYVIEW-2D server[39] and revised based on the tertiary
structure visualized with UCSF Chimera software.[40] Blue lines and green arrows indicate the loop and b-strand regions, respectively.
Connective orange lines between Cys residues indicate disulfide bridge formations. Below the secondary structure, the RSA is indicated, in
which the black and white squares represent completely buried (0-9 RSA) and fully exposed (90-100 RSA) amino acids, respectively. Putative
tertiary structure of AnAFP and FPAP was predicted in silico by I-Tasser,[41] and refined by ModRefiner.[42] Tertiary structure of PAF (Protein Data
Bank ID: 2mhv) served as a template to model the structure of AnAFP and FPAP. Question marks indicate that the secondary structure of
NFAP2 is under investigation.
Table 2. Minimal inhibitory concentrations (MICs) of crAFPs on different Candida species and their predicted binding affinity to human serum
albumin (HSA).
Species MIC (mM)
AnAFP PAFB* FPAP PAF* NFAP2
Applied medium
standard[30] diluted[28] standard[32] diluted[28] standard[50] diluted[50]
C. albicans 8–15 1 >24 4 36 1
C. glabrata n.d. 0.6 >24 2.5 2 0.3
C. guilliermondii n.d. n.d. >24 n.d. 0.6 0.3
C. inconspicua n.d. n.d. 24 n.d. n.d. n.d.
C. krusei n.d. 0.6 >24 5 72 2
C. lipolytica n.d. n.d. 24 n.d. n.d. n.d.
C. lusitaniae n.d. n.d. 24 n.d. >18 0.6
C. norvegica n.d. n.d. 24 n.d. n.d. n.d.
C. parapsilosis n.d. 0.6 >24 2.5 18 0.3
C. tropicalis n.d. n.d. >24 n.d. >18 0.3
C. zeylanoides n.d. n.d. >24 n.d. n.d. n.d.
Predicted binding affinity to HSA[65]
DG (kcal/mol) 9.15 8.88 13.80 11.09 12.16
Kd (M) 1.95e-07 3.07e-07 7.52e-11 7.33e-09 1.21e-09
*The MIC of PAF and PAFB on NAC was determined as described.[26] n.d.: not determined. Media applied in susceptibility tests: AnAFP – Yeast
Mold Medium (YM: 1% glucose, 0.3% malt extract, 0.5% peptone, and 0.3% yeast extract (w/v)), PAF and PAFB – Ten-fold diluted Potato
Dextrose Broth (PDB; Becton Dickinson), FPAP – Low Cationic Agar Medium (LCM: 2% glucose, 0.1% yeast extract, 0.05% peptone (w/v)),
NFAP2 – Roswell Park Memorial Institute 1640 medium (RPMI 1640; Sigma-Aldrich) as standard medium, and diluted Low Ionic Strength
Broth Medium (LCM: 0.5% glucose, 0.25% yeast extract, 0.0125% peptone (w/v)). DG is the binding free energy, Kd is the dissociation
constant. PPA-Pred2 (Protein-Protein Affinity Predictor) server for miscellaneous complexes was applied to calculate DG and Kd.[65]
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strength medium optimized for the investigation of crAFP
activity (Table 2).[50] Generally, it is typical for all members of
this protein group that high ionic strength media decrease the
in vitro antifungal efficacy.[27,44] In contrast to NFAP2,[29] all
anti-yeast crAFPs tested so far inhibit the growth of
filamentous fungi,[27,28,32] but were found inactive against
yeasts in standard HCCS test medium, for example, the P.
chrysogenum antifungal proteins PAF and PAFB show very
low activity against different Candida species in RPMI 1640
(unpublished results). One possible explanation for this
phenomenon is provided by the mechanism of action of
antifungal plant defensins. These cationic antifungal proteins
electrostatically attach to the negatively charged phospholipid
heads in the fungal plasma membrane before they exert their
antifungal effect. This electrostatic interaction is cation
sensitive by competition between the cationic antifungal
proteins and cations present in the medium for the binding
sites.[55] Antifungal efficacy of BP on Candida species has not
been tested yet, but the reported strong inhibitory activity on
baker‘s yeast Saccharomyces cerevisiae suggests a high
efficacy to inhibit the growth of other yeasts.[31]
Figure 3. Tertiary structure, hydrophobicity (Kyte-Doolittle scale of amino acids with colors ranging from blue for the most hydrophilic to white
at 0.0 to orange for the most hydrophobic) and electrostatic surface (Coulombic surface coloring of amino acids with colors ranging from dark
blue for positive charge to white at 0 to red for negative charge) (from up to down) of anti-yeast crAFPs isolated from Eurotiomycetes. The
first loop region and the g-core motif is indicated by black and grey, respectively. Cys residues and disulfide bridges are marked in yellow and
yellow lines, respectively. All structures were generated with UCSF Chimera visualization software using the respective annotated (Protein
Data Bank IDs: PAFB-2nc2, PAF-2mhv, BP-1uoy) or predicted (AnAFP and FPAP) .pdf file of tertiary structure, respectively.[40] Putative tertiary
structure of AnAFP and FPAP was predicted in silico by I-Tasser,[41] and refined by ModRefiner.[42] Based on the Ramachandran plot analysis,[43]
96.4% and 100% of the residues are in the favored and allowed position in AnAFP and FPAP, respectively. Tertiary structure of PAF (Protein
Data Bank ID: 2mhv) served as a template to model the structure of AnAFP and FPAP. Question marks indicate that the tertiary structure,
hydrophobicity and electrostatic surface of NFAP2 are under investigation.
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4.2 Anti-Candida Activity in Drug Combination
In combinatorial antimicrobial therapy two or more drugs are
administered simultaneously to treat an infection. This treat-
ment is applied when the infectious agent shows low
susceptibility or even resistance to one drug and/or the
prolonged high-dosage monotherapy can cause severe side-
effects in the host. Combination of antifungal agents
represents a more effective therapy than their single applica-
tion by shortening the treatment period and decreasing the
administered drug concentrations to avoid toxic adverse
effects.[56] Studies successfully demonstrated synergistic anti-
fungal effects in vitro and in vivo when crAFPs and licensed
antifungals or other drugs possessing a secondary antifungal
effect were combined.[27,57,58,59] As for anti-Candida activity,
the co-administration of NFAP2 and fluconazole in stand-
ardized clinical microbiological susceptibility tests inhibited
the in vitro growth of C. albicans and C. parapsilosis in a
synergistic way, but was neutral against C. krusei.[50] The
applicability of crAFPs in vivo was further shown in a mouse
infection model, where the synergistic anti-Candida efficacy
of NFAP2 in combination with fluconazole was proven
recently.[60] In contrast, no antagonistic mode of actions have
been observed so far, which underlines the potential of crAFPs
for anti-Candida polytherapy.[27,50]
4.3 Anti-Candida Mechanisms
The anti-Candida mechanisms of crAFPs are not fully under-
stood, and available data exist only for NFAP2,[29,50] PAF,[26,28]
and PAFB.[28] NFAP2 causes prompt plasma membrane
disruption in C. albicans indicating a fast and fungicidal
mechanism of action even in high cationic medium under
clinical susceptibility test conditions.[29,50] The fungicidal
mechanism reduces the risk of resistance development, and
further underlines the antifungal potential of NFAP2 under
in vivo conditions. PAF and PAFB also act candidacidal, but in
contrast to NFAP2, these proteins are not effective in high
ionic strength media.[28] Their mode of action was extensively
investigated in diluted complete media.[26,28] Both crAFPs are
internalized by C. albicans via an energy-dependent mecha-
nism before the plasma membrane of the Candida cells is
disrupted.[26,28] Apart from protein uptake, the induction of
reactive oxygen species is closely linked with the antifungal
activity of PAF, which was shown to be also effective against
C. albicans biofilm formation.[26] This antifungal mode of
action of PAF closely resembles that of PAF26, a de novo
designed, highly cationic synthetic antifungal hexapeptide.[61]
The observations made with NFAP2, PAF and PAFB suggest
that crAFPs of different crAFP groups interact with distinct
target(s) involved in the anti-Candida activity. Further detailed
investigations are necessary to identify the interaction mole-
cules.
5. Potential Therapeutic Applications and
Limitations
Several studies unambiguously demonstrated the fungal
selectivity of crAFPs as these proteins exhibit neither
hemolytic nor cytotoxic effects on mammalian cells in vi-
tro.[26,28,60,62,63] Intranasal and topical application of PAF proved
to be safe in a toxicity testing in mice: no adverse effects were
detected when the protein was administered at its highest
in vitro inhibitory concentration for Aspergillus fumigatus.[59]
In a subsequent study the in vivo antifungal potency of
intraperitoneally administered PAF was demonstrated with a
murine pulmonary aspergillosis model. The intranasal applica-
tion of PAF slightly delayed the mortality rate of the animals
in this experiment and its peritoneal co-administration with
amphotericin B even prolonged the survival suggesting
antifungal synergism between the two compounds.[64] A
murine vulvovaginitis model proved that NFAP2 significantly
decreases the cell number of fluconazole-resistant C. albicans
during the infection; furthermore its combination with
fluconazole enhances the activity.[60] These results promise a
safe in vivo administration of crAFPs as mono- or polyther-
apeutic agents in treatment of fungal infection. However, the
cation-sensitivity discussed above combined with poor bio-
availability could diminish their potential application as
systemic agents in an anti-Candida therapy. In silico predic-
tions show a possible high binding affinity of crAFPs to
human serum albumin based on the calculated low binding
free energy and dissociation constant (Table 2).[65] Keeping
these limitations in mind, the topical application of crAFPs to
treat dermal and mucosal infections could be more promising.
6. De Novo Designed Synthetic Peptide
Derivatives of crAFPs
6.1 Structure-Activity Determinants of crAFPs for
Anti-Candida Activity
Functional mapping combined with antifungal activity testing
of synthetic peptide fragments derived from crAFPs provides a
feasible basis to study their structure-activity determinants.[50]
These antifungal active peptide motifs can serve as potential
new antifungal compounds or as templates for rational peptide
design to improve the features of the protein to meet the
requirements for safely applicable and effective antifungal
therapy.[26,50] The crAFPs from Eurotiomycetes that have
already been isolated and characterized as well as those which
can be predicted by genome mining contain an evolutionary
highly conserved consensus sequence ([GXC]-[X3-9]-[C]) that
can also be found in small and Cys-stabilized antimicrobial
proteins from other organisms.[26,66] This motif, the so-called g-
core, localizes in the flexible loop regions at the N- or C-
terminus (Figure 3), or in the center of crAFPs in forward
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(dextromeric isoform) or reverse direction (levomeric isoform)
(Table 1).[26] The impact of the g-core motif on the anti-
Candida activity has been investigated recently in PAF. A
synthetic peptide spanning this PAF motif located in loop 1
exhibited antifungal activity per se.[26] This antifungal efficacy
strongly depends on the amino acid composition. The increase
of the peptide net charge (at pH 7) and of its hydrophilicity by
respective amino acid substitutions dramatically improved the
antifungal efficacy of the synthetic g-core peptide.[26] Sim-
ilarly, the anti-Candida activity of PAF could be significantly
increased when the same amino acids as in the synthetic
peptides were exchanged in the g-core of the full-length
protein.[26] In contrast, the C-terminally located g-core of
NFAP2 seems to play no role in anti-Candida activity, most
probably, because this motif has an almost neutral charge and
contains numerous hydrophobic amino acids.[50] Instead, the
NFAP2 g-core presumably supports correct protein folding.[50]
Interestingly, a synthetic positively charged and hydrophilic
peptide deduced from loop 1 of NFAP2 was found function-
ally active.[50]
6.2 In Vitro Antifungal Effect of crAFP Peptide Derivatives
Synthetic peptides with antifungal activity spanning the PAF
g-core and the N-terminal loop 1 of NFAP2 are unstructured,
and less active than the full-length proteins (Table 3 and
Table 4).
This lower efficacy could be the consequence of their non-
specific antifungal mode of action against yeasts that differs
from that of the full-length protein (e.g. immediate plasma
membrane disruption) or because other protein motifs may
contribute to full antifungal activity.[26,50] The anti-Candida
activity of these peptides does not depend on the primary
structure, because scrambled peptide variants thereof show the
same efficacy as the native peptides.[26,50] This observation
allows the conclusion that the overall physicochemical proper-
ties (such as the net charge and the hydrophilicity in Table 3)
determine the anti-Candida efficacy, and the peptides do not
have amino acid sequence-specific binding targets in the yeast
cell. Rational design of the PAF g-core peptide supports this
claim (Table 3). Specific amino acid substitutions that elevate
the positive net charge and reduce the hydrophobicity render
the peptide variant similarly effective against C. albicans and
NACs than the full-length protein variant (Table 4). These
rational de novo designed PAF g-core peptide variants do not
show hemolytic activity and do not affect the viability of
primary human skin cells, which promises their potential
therapeutic application.[26]
7. Summary and Outlook
The outlined features render the crAFPs and peptide deriva-
tives promising candidates for potential clinical anti-Candida
therapy. However, the poor pharmacokinetic properties, and
the reduced antifungal efficacy in high ionic strength environ-
ment hampers their applicability. Rational design and appro-
priate formulations might overcome these limitations. Consid-
ering the increasing number of antifungal drug-resistant
Candida strains and the fact that Candida species mainly
affect the skin or mucosa posing a risk to become fatal
invasive infections in immunocompromised patients the
administration of crAFPs or peptide derivatives could be more
promising than treatment with a conventional drug.[67] The
crAFPs could also be considered as substances in combination
drug products to facilitate the antifungal effect of already
applied compounds.[68] Different formulations of crAFPs and
Table 3. Amino acid sequence and in silico predicted physicochemical properties of synthetic crAFP-derived anti-Candida peptides.
Number of amino
acids
Molecular weight
(kDa)[34]
Number of
Cys
Number of Lys/Arg/
His
Theoretical isoelectric
point[34]
Estimated
charge
at pH 7[35]
GRAVY[34]
NFAP2 mid-N terminal region (Fr-4): NNC(SH)KHKKGSGC(SH)[50]
11 1.2 2 3/0/1 9.39 +3.1 1.682
PAF g-core (Pg): KYTGKC(SH)TKSKNEC(SH)K[26]
14 1.6 2 5/0/0 9.51 +3.8 1.814
PAF g-core variant (Pgvar): KYTGKC(SH)YKKKNEC(SH)K[26]
14 1.7 2 6/0/0 9.63 +4.8 2.079
Rational designed PAF g-core (Pg8pt): KYTGKC(SH)KTKKNKC(SH)K[26]
14 1.7 2 7/0/0 10.04 +6.8 2.064
GRAVY: grand average of hydropathy value.
Table 4. Minimal inhibitory concentrations (MIC) of synthetic pep-
tides spanning the g-core motif of NFAP2 and PAF (see Table 3) on
C. albicans and NACs.
Species MIC (mM)
NFAP2[50] PAF[26]*
Fr-4 Pg Pgvar Pg8pt
C. albicans 43 10 2.5 1.3
C. glabrata n.d. >20 n.d. >20
C. krusei 43 20 n.d. 2.5
C. parapsilosis 43 10 n.d. 1.3
*The MIC of the synthetic PAF-derived g-core peptides on NACs was
determined as described.[26] n.d.: not determined.
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their peptide derivatives, such as liposome or nanocarrier
encapsulation, could improve the bioavailability and enhance
the pharmacokinetic properties as it has been proven already
for several antibacterial peptides.[69] In addition to pharmacoki-
netic improvements, further intensive in vivo investigations
focusing on the therapeutic application are essential to
facilitate the introduction of crAFPs in clinical therapy.
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